Načítá se...
Seamless Phase I/II Adaptive Design For Oncology Trials of Molecularly Targeted Agents
In dose-finding trials of chemotherapeutic agents, the goal of identifying the maximum tolerated dose is usually determined by considering information on toxicity only, with the assumption that the highest safe dose also provides the most promising outlook for efficacy. Trials of molecularly targete...
Uloženo v:
| Vydáno v: | J Biopharm Stat |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4363077/ https://ncbi.nlm.nih.gov/pubmed/24904956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2014.920873 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|